Asset
RIDINILAZOLE
Summit Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02092935 | phase2 | completed | 2014-04-01 | 2015-10-01 | Summit Therapeutics | A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) |
FDA applications (0)
This company has no applications containing this asset.